11/1612015
`
`Mylan Pharmaceuticals Inc.: Private Company Information - Businessweek
`
`Pharmaceuticals
`Company Overview of Mylan Pharmaceuticals Inc.
`
`N011ember 16, 2015 6:24PM ET
`
`People
`
`Key Exeartives For Mylan PllarmaceuUc.ls Inc.
`
`Mr. Joseph Duda
`Presilent
`
`Mr. John Deiriggi
`Senior Voce Presilent
`
`Ms. Colleen Ostrowski
`Treasurer
`Age:41
`
`Mr. Daniel Caron
`Vice President of Generic Bus ness Development
`
`Compensation as of Fiscal Year 2015.
`
`Company Overview
`Mylan Phannaceuticals Inc. researches, develops,
`manufactures, mar1c:ets, and distributes generic
`phamlaceutical products. Its prtXIucts include
`amlodipine besylate and atONastatin calcium tablets
`for the treatment of hypertension; levetiracetam
`extended-release tablets for the treatment of partial
`onset seizures in patients of over 16 years of age
`with epilepsy; eprosartan mesylate tablets for treating
`hypertension; doxycycline hyclate delayed-release
`tablets; and fluvastatin capsules for the treatment of
`familial and nonfamilial hypercholesterolemia, mixed
`dyslipidemia, and secordary prevention of
`cardiovascular diseases. The company also provides
`olanzapine tablets for the treatment of schizophrenia,
`acute treatment of manic or mixed episodes
`associated with bipolar 1 disorder, and maintenance
`treatment of bipolar 1 disorder; USP tablets for the
`treatment of hyperprolactinemic disorders; tablets for
`alle~gy medcation; nevirapine tablets for combination
`antiretroviraltreatment of HIV -1 infection; acyclovir
`ointment USP for the management of initial genital
`herpes; and pheny1oin chewable tablets for the
`control c:J generalized tonic-clonic and partial
`seizures, and preventior and treatment of seizures
`occooing during or following neurosurgery. In
`addition, it c:Jfers clopidogrel tablets for acute
`caonary syrdome; and for patients with a recent
`history c:J myocardial infarction, stroke, or
`established peripheral arterial disease. Further, the
`company provides norethindrone tablets to prevent
`pregnancy. Its prodlcts are also used for the
`treatment of angina to arthritis, depression, diabetes,
`Par1c:inson's disease, schizophrenia, and sleep
`disorders. The company was formerly known as
`Milan Pharmaceuticals Inc. and changed its name to
`Mylan Pharmaceuticals Inc. in AL9Jst 1973. The
`t;UIIIp<my Wd::l fuurollt;;J ill 1961 "''<J is'-"'>;.,.) in
`Morgantown, West Virginia. Mylan Pharmaceuticals
`Inc. operates as a subsidiary of Mylan N.V.
`
`Hide Detailed Description
`
`781 O"lestnut Ridge Road
`Morgantown, WV 26505
`
`Phone 724-514-1800
`304-598-5406
`Fu
`
`United States
`
`Founded in 1961
`
`Mylan Pharmaceuticals Inc. Key Developments
`Appeals Court Affirms Shire pic's Vyvanse (lisdexamfetamine Dimesylate) Patents Valid
`Until2023
`Sep 25 15
`Shire pic announced that the Court of Appeals of the Federal Circuit has upheld the summary judQment
`ruling c:J the U.S . District Court for the District of New Jersey that certain claims of the patents protecting
`Vyvanse Oisdexamfetamine dimesylate) are valid. Shire's lawsuit included all ot the known phalmaceutical
`manufacturers that filed Abbreviated New Drug Applications with the U.S. Food and Drug Administration
`seeking to mar1c:et generic versions of Vyvanse, along with their Active Pharmaceutical Ingredient
`manufacturer of lisdexamfetamine dimesylate API. The ANDA-{lefendants are Actavis LLC/Actavis
`Elizabeth LLC; Amneal Pharmaceuticals, LLC; Mylan Pharmaceuticals lnc./Mylan Inc.; Roxane Laboratories
`
`http:/lwww.bloomberg.com/researchlstockslprivate/snapshot.asp?privcapld=4222931
`
`1/3
`
`PAGE 1 OF 3
`
`SENJU EXHIBIT 2187
`INNOPHARMA v SENJU
`IPR2015-00903
`
`

`
`Mylan Pharmaceuticals Inc.: Private Company Information ­ Businessweek
`11/16/2015
`Inc.; and Sandoz Inc. The API manufacturer and supplier to each of the ANDA­defendants is Johnson
`Matthey Inc./Johnson Matthey Pharmaceutical Materials. The ruling prevents the ANDA defendants from
`launching generic versions of Vyvanse until the expiration of these patents in 2023. The defendants may
`move for rehearing at the Federal Circuit, or may file a petition at the U.S. Supreme Court. The Court of
`Appeals of the Federal Circuit affirmed the District Court’s summary judgment ruling that 18 patent claims
`from four of the FDA Orange Book­listed patents for Vyvanse are valid. The ANDA defendants’ infringement
`of these claims was not contested on appeal. These patent claims cover Vyvanse’s active ingredient, the
`lisdexamfetamine dimesylate compound, and a method of using lisdexamfetamine dimesylate for the
`treatment of ADHD. As to the API­manufacturer, the court of appeals of the Federal Circuit found that
`Johnson Matthey was not liable for the API it sold the ANDA defendants up to this point because it did not
`submit an ANDA.
`
`Noven Pharmaceuticals Inc. and Hisamitsu Pharmaceutical Co., Inc Sues Mylan N.V.,
`Mylan Pharmaceuticals Inc. and Mylan Technologies Inc
`May 5 15
`Mylan N.V. confirmed that it and its subsidiaries Mylan Pharmaceuticals Inc. and Mylan Technologies Inc.
`have been sued by Noven Pharmaceuticals Inc. and Hisamitsu Pharmaceutical Co., Inc., in connection with
`the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA)
`for Estradiol Transdermal System, USP, "Twice­Weekly" 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and
`0.1 mg/day. This product is the generic version of Minivelle®, which is indicated for the treatment of
`moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal
`osteoporosis. Mylan believes that it is the first company, or among the first companies, to have filed a
`substantially complete ANDA containing a Paragraph IV certification for this product and expects to be
`eligible for 180 days of marketing exclusivity upon receiving final FDA approval. The plaintiffs filed suit
`against the Mylan companies in the United States District Court in the District of Delaware.
`
`Mylan Pharmaceuticals Inc. Wins $6,625,235.45 Federal Contract
`May 1 15
`Mylan Pharmaceuticals Inc. won a $6,625,235.45 federal contract from the U.S. Department of Veterans
`Affairs' National Acquisition Center for loperamide hydrochloride capsule.
`
`Similar Private Companies By Industry
`Company Name
`InCode BioPharmaceutics, Inc.
`Supplements Liquidating Trust, LLC
`BrainCells Inc.
`Antyra, Inc.
`Biochemie US, Inc.
`
`Region
`United States
`United States
`United States
`United States
`United States
`
`Report Data Issue
`
`From Around the Web
`
`Recent Private Companies Transactions
`Type
`Date
`
`Target
`
`No transactions available in the past 12 months.
`
`
`
`by Taboola Sponsored Links 
`
` 
` 
`
`Here's 4 Examples of How Businesses are Using CRM. Sign Up for a Free Demo
`SalesForce
`
`4 in 5 Americans Are Ignoring Buffett's Warning
`The Motley Fool
`
`Meet The Man Who Is Disrupting a $13 Billion Razor Industry
`Dollar Shave Club
`
`Will This Startup Kill The ETF Revolution?
`Yahoo  Finance   Motif Investing
`
`Thinking about getting Solar Panels? Read This First
`Solar America
`
`http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=4222931
`
`2/3
`
`PAGE 2 OF 3
`
`

`
`11/16/2015
`
`Mylan Pharmaceuticals Inc.: Private Company Information ­ Businessweek
`
`New Law: Turn $5,000 into $6.5 Million
`Crowdability
`
`http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=4222931
`
`3/3
`
`PAGE 3 OF 3